Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04145700 · OUTCOME

Complete Response (CR): Percentage of Participants Who Achieve CR

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma · Source last updated 2023-09-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
80% Confidence Interval
Time frame
Baseline Up to 6.94 months

What was measured

CR is a disappearance of all target and non-target lesions and normalization of tumor marker level.

Analysis population: All randomized participants.

Groups in this outcome

Ramucirumab + Gemcitabine + Docetaxel

Participants received intravenous infusions of ramucirumab 9 mg/kg, gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.

Gemcitabine + Docetaxel

Participants received intravenous infusions of gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ramucirumab + Gemcitabine + Docetaxel16
Gemcitabine + Docetaxel7

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: 80% Confidence Interval
GroupValueSpreadLowerUpperComment
Ramucirumab + Gemcitabine + Docetaxel0Not reported013.4Not reported
Gemcitabine + Docetaxel0Not reported028Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        13.4
        value
        0
      2. group Id
        OG001
        lower Limit
        0
        upper Limit
        28
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    2. group Id
      OG001
      value
      7
    units
    Participants
description
CR is a disappearance of all target and non-target lesions and normalization of tumor marker level.
dispersion Type
80% Confidence Interval
groups
  1. description
    Participants received intravenous infusions of ramucirumab 9 mg/kg, gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.
    id
    OG000
    title
    Ramucirumab + Gemcitabine + Docetaxel
  2. description
    Participants received intravenous infusions of gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.
    id
    OG001
    title
    Gemcitabine + Docetaxel
param Type
NUMBER
population Description
All randomized participants.
reporting Status
POSTED
time Frame
Baseline Up to 6.94 months
title
Complete Response (CR): Percentage of Participants Who Achieve CR
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice